Industry making moves towards better utilizing clinical research as a care option.
For seven years, The Conference Forum has hosted the CRAACO® event, which, as stated on its website, through the collaboration of patient advocates, research physicians and nurses, FDA reps, pharma clinical operation executives, and technology companies has provided many case studies as pathways for industry to follow. The organization has also added a dedicated quarterly newsletter, podcasts, and webinars—all toward the forward motion of CRAACO.
It is no easy feat to get two huge behemoths to join together. Pharmaceutical drug development and healthcare systems are in the same pool of the overall healthcare industry. Treating people with approved therapies and medicines is only 14% of the overall healthcare spend, by some reports, but the overall benefits of medicines clearly cannot be doubted. However, the divide of clinical trials on one hand, and healthcare on the other, is fraught with challenges—data, terminology, process, education, and access.
But at the end of the day, it is the people who need these treatments as options to improve their health; that is the central concern, along with proving the efficacy and safety of the medicines.
It is no surprise that clinical trials, as an industry, has turned toward patient centricity, leaving the word “subjects” behind as too antiseptic and separating the person from the trial. “Patients,” for some, is too broad of a terminology, and most agree that “participants” is the best term to describe a person in a clinical trial. This is discussed in a recent podcast with executives from SMO Panthera Biopartners.
In a separate podcast, Christine McSherry and Mindy Leffler, the co-founders of the CRO Casimir, acquired in March by another CRO, Emmes, talk about the true meaning of patient-focused drug development. Though heart-wrenching, the two describe how genuine patient centricity can be achieved in clinical trials, when access to investigational therapies is the only real option for those patients with diseases that give them so little time.
In our lead feature this month, the topic of CRAACO is explored more toward the data piece of the puzzle. Not a bad place to start for researchers and health professionals, in the EHR. But the end story will always be the people.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FSP Outsourcing in Clinical Research: Trends and Opportunities
June 9th 2025When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.